McKinsey L. Goodenberger

Molecular Biology · 2012

A researcher in the Science corpus: 1 paper; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom McKinsey L. Goodenberger trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. H. Ohgaki
  2. Manel Esteller
  3. P. Kleihues
  4. Takuya Watanabe
  5. S. Nobusawa
  6. T. Papagiannakopoulos

Papers from McKinsey L. Goodenberger's perspective

Ordered by how strongly the researchers McKinsey L. Goodenberger trusts endorse each paper. Same corpus, a different order for every researcher.

  1. An Integrated Genomic Analysis of Human Glioblastoma Multiforme (Science)
  2. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (Cancer Cell)
  3. IDH1 and IDH2 mutations in gliomas. (New England Journal of Medicine)
  4. Genetic pathways to primary and secondary glioblastoma. (American Journal of Pathology)
  5. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. (Cancer Cell)
  6. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 (Cancer Cell)
  7. IDH mutation impairs histone demethylation and results in a block to cell differentiation (Nature)
  8. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. (American Journal of Pathology)
  9. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype (Nature)
  10. Epidemiology and etiology of gliomas (Acta Neuropathologica)

Their papers